Recent patents concerning modulators of protein kinase C

Recent Patents on DNA and Gene Sequences

Volumn 7, Issue 1, 2013, Pages 74-81

  Sanchez Bautistaa, Sonia ^a   Nicolas, Francisco E ^b  

^a CATHOLIC UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Activators; Antisense oligonucleotide; Biomarkers; Inhibitors; Modulators; Protein kinase C

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 3 (8 AMINOMETHYL 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL) 4 (1 METHYL 3 INDOLYL) 1H PYRROLE 2,5 DIONE; 3 [1 (3 AMINOPROPYL) 3 INDOLYL] 4 (1 METHYL 3 INDOLYL) 1H PYRROLE 2,5 DIONE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; ALPHA TOCOPHEROL; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BISINDOLYLMALEIMIDE; BRYOSTATIN; CYCLOSPORIN; DELCASERTIB; GO 7612; GO 7852; INDOLYLMALEIMIDE DERIVATIVE; MALEIMIDE DERIVATIVE; MITOMYCIN; MYR SIYRRGARRWRKL PEPTIDE; N,N BIS (AMIDO) 2 AMINO 4 IMINONAPHTHALEN 1 ONES; NERISTATIN; PROTEIN KINASE C; PROTEIN KINASE C ALPHA INHIBITOR; PROTEIN KINASE C INHIBITOR; RO 31 0432; SAFINGOL; STAUROSPORINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; BLOOD VESSEL PERMEABILITY; CARCINOGENESIS; CARDIAC GRAFT REJECTION; CHRONIC PAIN; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME REGULATION; ENZYME STRUCTURE; GRAFT REJECTION; HUMAN; IC 50; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; ISCHEMIA; METASTASIS; NEOPLASM; NERVE FIBER REGENERATION; NEUROPATHIC PAIN; NONHUMAN; ORGAN TRANSPLANTATION; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSPECIFIED SIDE EFFECT;

AXONS; BRAIN NEOPLASMS; ENZYME ACTIVATORS; HUMANS; MYOCARDIAL INFARCTION; NEOPLASMS; NEURODEGENERATIVE DISEASES; OLIGORIBONUCLEOTIDES, ANTISENSE; PAIN; PATENTS AS TOPIC; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; TRANSPLANTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875972921     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872215611307010011     Document Type: Review

References (56)

1. Hofmann J. The potential for isoenzyme selective modulation of protein kinase C. FASEB J 1997; 11: 649-669.
2. Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001; 101: 2353-2364.
3. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9: 484-496.
4. Ohno S, Nishizuka Y. Protein kinase C isotypes and their specific functions: prologue. J Biochem 2002; 132: 509-11.
5. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998; 332: 281-292.
6. Newton AC, Johnson JE. Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim Biophys Acta 1998; 1376: 155-72.
7. Laher I., Zhang JH. Protein kinase C and cerebral vasospasm. J Cereb Blood Flow Metab 2001; 21: 887-906.
8. Murray MA, Faraci FM, Heistad DD. Role of protein kinase C in constrictor responses of the rat basilar artery in vivo. J Physiol 1992; 445: 169-179.
9. Uhl MW, Kochanek PM, Schiding JK, Nemoto EM. Effect of phorbol myristate acetate on cerebral blood flow in normal and neutrophil-depleted rats. Stroke 1993; 24: 1977-1982.
10. Akopov SE, Sercombe R, Seylaz J. Endothelial dysfunction in cerebral vessels following carotid artery infusion of phorbol ester in rabbits: the role of polymorphonuclear leukocytes. J Cereb Blood Flow Metab 1994; 14: 1078-1087.
11. Jin Y, Sagher O, Thai QA, Kassell NF, Lee KS. The effects of papaverine on phorbol dibutyrate-induced vasoconstriction in brain slice microvessels. J Neurosurg 1994; 81: 574-578.
12. Liu Y, Lei S, Gao X, et al. PKCβ inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes. Clin Sci 2012 122 161-173
13. Manicassamy S. Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis. Curr Opin Investig Drugs 2009; 10:1225-1235.
14. Wagner J, von Matt P, Faller B, et al. Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis. J Med Chem 2011; 54: 6028-6039.
15. Kwon MJ, Wang R, Ma J, Sun Z. PKC-Θ is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection.Endocr Metab Immune Disord Drug Targets 2010 10 367-372
16. Zhao C, Leitges M, Gereau RW. Isozyme-specific effects of protein kinase C in pain modulation. Anesthesiology 2011; 115: 1261-1270.
17. Alkon DL, Sun MK, Nelson TJ. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol Sci 2007; 28: 51-60.
18. Wang Z, Fukushima H, Inuzuka H, et al. Skp2 is a promising therapeutic target in breast cancer. Front Oncol 2012; 4:1(57).
19. Alvarado Y, Giles FJ, Swords RT. The PIM kinases in hematological cancers. Expert Rev Hematol 2012; 5: 81-96.
20. Bareschino MA, Schettino C, Rossi A, Maione P, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis 2011; 3: 122-133.
21. Bennett CF, Dean N. Oligonucleotide inhibition of Protein kinase C. US0055882927, 1999.
22. Bennett CF, Dean NM, Holmlund JT, Dorr FA. Oligonucleotide inhibition of Protein kinase C. US006537973, 2003.
23. Schwartz GK, Albino AP. Combinations of PKC inhibitors and therapeutic agents for treating cancers. US005821072, 1998.
24. Lu Z. Cancer treatment with compounds inhibiting PKC alpha. US20080009511, 2008.
25. Saito N, Kose A, Ito A, et al. Immunocytochemical localization of beta II subspecies of protein kinase C in rat brain. Proc Natl Acad Sci USA 1989; 86: 3409-3413.
26. Papadopoulos V, Hall PF. Isolation and characterization of protein kinase C from Y-1 adrenal cell cytoskeleton. J Cell Biol 1989; 108: 553-567.
27. McLaughlin S, Wang J, Gambhir A, Murray D. PIP(2) and proteins: interactions, organization, and information flow. Annu Rev Biophy Biomol Struct 2002; 31: 151-175.
28. Mochly-Rosen DD, Kim J, Thorme S. Inhibition of tumor metastases using protein kinase C (PKC) inhibitors. US20090137493, 2009.
29. Grimes K, Chen LE. Method of treating acute st-elevation myocardial infarction with a delta PKC antagonist. US20090318351, 2009.
30. Edvinsson L, Ansar S. Isquemic disorder or disease inhibitors. US20100152248, 2010.
31. Mochly-Rosen DD, Koyanagi T, Inagaki K, Ootani A. Suppression of inflammation associated with transplantation using an epsilon PKC inhibitor. US20090124553, 2009.
32. van Eis M, Von Matt P, Wagner J, Evenou JP, Schuler W. Indolmaleimide derivatives as PKC inhibitors. US007648989, 2010.
33. Korn A, Lake P, Mailbucher A. Use of PKC inhibitors in transplantation. US20100075997, 2010.
34. MacLean D, Yin Q. Methods of use of epsilon inhibitor compounds for the attenuation of pain. US008017583, 2011.
35. Messing RO, Levine JD. Use of inhibitors of Protein kinase C epsilon to treat pain. US006376467, 2002.
36. Messing RO, Levine JD. Use of inhibitors of Protein kinase C epsilon to treat pain. US006686334, 2004.
37. Battaini F. Protein kinase C isoforms as therapeutic targets in nervous system disease states. Pharmacol Res 2001; 44: 353-361.
38. Le Merrer J, Noguès X. Cognitive neuropharmacology: new perspectives for the pharmacology of cognition. Pharmacol Res 2000; 41: 503-514.
39. Tanaka C, Nishizuka Y. The protein kinase C family for neuronal signaling. Annu Rev Neurosci 1994; 17: 551-567.
40. Maher P. How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J Neurosci 2001; 21: 2929-2938.
41. Horner PJ, Gage FH. Regenerating the damaged central nervous system. Nature 2000; 407: 963-970.
42. Schwab ME. Repairing the injured spinal cord. Science 2002; 295: 1029-1031.
43. Schwab ME, Bartholdi D. Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev 1996; 76: 319-370.
44. He Z, Koprivica V, Sivasankanan R. Axon regeneration with PKC inhibitors. US20090220570, 2009.
45. Antonetti DA, Sundstrom JM, Smith CD. Protein kinase C zeta inhibition to treat vascular permeability. US20080021036, 2008.
46. Eigler A, Sinha B, Hartmann G, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997; 18: 487-92.
47. Bennett CF, Dean N. Antisense oligonucleotides against human Protein kinase C. US005916807, 1999.
48. Dean NM. Antisense oligonucleotide modulation of human Protein kinase C-γ expression. US006235723, 2001.
49. Choi DS, Wang D, Yu GQ, et al. PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci USA 2006; 103: 8215-8220.
50. Nelson TJ, Alkon DL. PKC-activating compounds for the treatment of neurodegenerative diseases. US 20100022645, 2010.
51. Alkon, D. Methods for Alzheimeŕs disease treatment and cognitive enhancement. US20110021508, 2011.
52. Diaz-Meco MT, Municio MM, Sanchez P, Lozano J, Moscat J. Lambda-interacting protein, a novel protein that specifically interacts with the zinc finger domain of the atypical protein kinase C isotype lambda/iota and stimulates its kinase activity in vitro and in vivo. Mol Cell Biol 1996; 16: 105-114.
53. Selzer E, Okamoto I, Lucas T, Kodym R, Pehamberger H, Jansen B. Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage. Melanoma Res 2002; 12: 201-209.
54. Murray NR, Fields AP. Atypical protein kinase C iota protects human leukemia cells against drug-induced apoptosis. J Biol Chem 1997; 272: 27521-27524.
55. Jin Z, Xin M, Deng X. Survival function of protein kinase C iota as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone-activated bad kinase. J Biol Chem 2005; 280: 16045-16052.
56. Acevedo-Duncan M, Patel R. Detection of PKC-iota as a biomarker for brain tumorigenesis. US007482131, 2009.